In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, aimed at adults who are not using insulin but still want detailed glucose ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom CGM systems provide automatic blood glucose updates every five minutes. FreeStyle Libre sensors can last up to 15 days and no longer need frequent scanning for updates. Both Dexcom and ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

The Federal Circuit upheld an administrative tribunal’s decision to nix six claims from a DexCom Inc. patent covering implantable sensors used to monitor patients’ blood glucose levels. DexCom sued ...

DexCom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, DexCom has captured an impressive slice of ...

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...